Despite the impact of companies like Impossible Foods, which markets plant-based imitation meat products,…
Category: Gene Modification
Home /
Intellia Therapeutics, based in Cambridge, Massachusetts, reported promising results from the Phase II clinical…
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases,…
When CRISPR was discovered in 1987, it transformed biotech by offering a way to…
RNA editing is emerging as a promising and potentially safer alternative to therapies that…
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into…
Gene therapy continues to emerge as a promising approach in the treatment and prevention…
Gene therapy has revolutionized the field of medical research by offering potential treatments for…
Recent years have seen increased research interest in the potential of chimeric antigen receptor…
Research results published in Nature this month demonstrate that chimeric antigen receptor (CAR) T-cell…
CAR-T is an immunotherapy that is currently used to treat blood cancers and is…
Transthyretin amyloidosis (ATTR amyloidosis) is a rare but fatal disease marked by clumping and…
A common refrain in science fiction movies is the cautionary statement, “Just because we…
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
Introduction Changes in how clinical trials are managed in the European Union (EU), mandated by the European Union Clinical Trial Regulation 536/2014 (EU CTR),…
NEWARK, Delaware, June 26, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new laboratory…
NEWARK, Delaware, June 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new clinical…
NEWARK, Delaware, May 21, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), continues to expand and align its…
Could Gene Therapy in Cows Slow Climate Change?
October 28, 2024
Despite the impact of companies like Impossible Foods, which markets plant-based imitation meat products, the demand for beef has never been higher. As of today,
Advancing CRISPR-Based Treatment for Rare Swelling Disease
September 30, 2024
Intellia Therapeutics, based in Cambridge, Massachusetts, reported promising results from the Phase II clinical trial of NTLA-2002, a CRISPR-based therapy targeting hereditary angioedema (HAE), a
RNAi Breakthrough in Heart Disease Treatment
August 12, 2024
Alnylam Pharmaceuticals, which specializes in developing RNA interference (RNAi) therapeutics to treat genetic diseases, has announced promising clinical trial results for their drug Amvuttra® (vutrisiran)
Jumping Genes: A New Frontier in Gene Editing
August 5, 2024
When CRISPR was discovered in 1987, it transformed biotech by offering a way to target genetic diseases thought to be untreatable. Although it has versatile
RNA Editing: A Safer Alternative in Genetic Medicine?
June 17, 2024
RNA editing is emerging as a promising and potentially safer alternative to therapies that modify an individual’s DNA. In December 2023, patients were treated in
The CAR-T Conundrum: Are Cutting-Edge Therapies Causing Cancer?
June 10, 2024
In November 2023, the U.S. Food and Drug Administration (FDA) announced an investigation into chimeric antigen receptor (CAR) T-cell therapies, questioning if these promising cancer
What Is a Vector in Gene Therapy?
September 27, 2023
Gene therapy continues to emerge as a promising approach in the treatment and prevention of a wide range of disorders and diseases. Central to the
How Are Viruses Used in Gene Therapy?
September 20, 2023
Gene therapy has revolutionized the field of medical research by offering potential treatments for genetic disorders and diseases previously considered untreatable or incurable. A key
Precision Steering of CAR-T Therapies May Effectively Target More Tumor Types
March 13, 2023
Recent years have seen increased research interest in the potential of chimeric antigen receptor (CAR)-T cancer therapies. This approach uses genetic engineering to modify T
Cancer Cure? 10-Year Leukemia Remission Reported with Personalized T-Cell Therapy
February 21, 2022
Research results published in Nature this month demonstrate that chimeric antigen receptor (CAR) T-cell therapy, which uses engineered T-cells to target cancer, held leukemia at
CRISPR and the Continuing Quest for CAR-T Safety and Durability
October 27, 2021
CAR-T is an immunotherapy that is currently used to treat blood cancers and is in clinical trials to treat other cancers as well. This treatment
Clinical Trial Shows In Vivo CRISPR-Cas9 Therapy Effective Against Rare Disease
August 22, 2021
Transthyretin amyloidosis (ATTR amyloidosis) is a rare but fatal disease marked by clumping and accumulation of mutated, misfolded transthyretin proteins in peripheral nerves and cardiac
Determining “Responsible Clinical Use” in Heritable Human Genome Editing
March 22, 2021
A common refrain in science fiction movies is the cautionary statement, “Just because we can doesn’t mean we should.” As new technologies such as CRISPR/Cas9
Introduction Researchers are developing novel, safer treatments for cancer, but bringing new oncology therapies to market is challenging. This white paper will examine the…
Introduction As global obesity rates continue to rise, the search for effective treatments is more critical than ever. Obesity is associated with an increased…
Introduction Changes in how clinical trials are managed in the European Union (EU), mandated by the European Union Clinical Trial Regulation 536/2014 (EU CTR),…
NEWARK, Delaware, June 26, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new laboratory…
NEWARK, Delaware, June 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), is pleased to announce new clinical…
NEWARK, Delaware, May 21, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a leading global contract research organization (CRO), continues to expand and align its…
